Joseph W. Chow
Research Subjects
Joseph W. Chow has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
Marcus J. Zervos
Division of Infectious Diseases,1 Department of Biochemistry and Molecular Biology, Wayne State University,2 Research and Medical Services, John D. Dingell VA Medical Center, Detroit, Michigan 48201,4 Research Institute, William Beaumont Hospital, Royal Oak, Michigan 480733
5 shared publicationsDon B. Clewell
Division of Infectious Diseases,1 Department of Biochemistry and Molecular Biology, Wayne State University,2 Research and Medical Services, John D. Dingell Veterans Affairs Medical Center, Detroit, Michigan 48201,5 Departments of Biologic and Materials Sciences,3 Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan 481094
4 shared publicationsSusan M. Donabedian
Division of Infectious Diseases,1 Department of Biochemistry and Molecular Biology, Wayne State University,2 Research and Medical Services, John D. Dingell VA Medical Center, Detroit, Michigan 48201,4 Research Institute, William Beaumont Hospital, Royal Oak, Michigan 480733
4 shared publicationsTheresa A. Snyder
Merck Research Laboratories, North Wales, PA, USA
4 shared publicationsVilas Satishchandran
Merck Research Laboratories North Wales, PA, USA
4 shared publicationsKathleen McCarroll
Merck Research Laboratories, North Wales, PA, USA
3 shared publications
Latest Publications
- Open Access
- 21 November 2025
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (1) , 183-195
Microbiological, Clinical, and Pharmacokinetic/Pharmacodynamic Data to Support EUCAST Aztreonam–Avibactam Minimum Inhibitory Concentration Susceptibility Breakpoints Against Enterobacterales
Introduction Aztreonam–avibactam was approved for adults with limited treatment options for multiple infections due to aerobic Gram-negative organisms in the European Union and for complicated intra-abdominal infection in the US, following the phase 3 REVISIT and ASSEMBLE trials. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) assigned minimum inhibitory concentration (MIC) breakpoints for aztreonam–avibactam against Enterobacterales of susceptible ≤ 4 mg/l and resistant > 4 mg/l. Methods A comprehensive synthesis of data supporting MIC breakpoint determination is summarized, including: joint probability of pharmacokinetic/pharmacodynamic target attainment (JPTA) analyses (based on population pharmacokinetic modeling) for aztreonam–avibactam dose selection; MIC distributions of target pathogens; clinical and microbiological efficacy outcomes; and exposure–response analyses. Results Among 100,228 Enterobacterales isolates, including 2449 metallo-β-lactamase-positive isolates from global surveillance studies (2017–2021), 99% had aztreonam–avibactam MICs of ≤ 8 mg/l. At MIC = 8 mg/l, the predicted JPTA at steady state was 89% to > 99% across subgroups of varying renal function, based on approved doses for aztreonam–avibactam. Clinical trial isolates fell within the same MIC distribution as surveillance studies. There was no evidence of decreased favorable microbiological responses with increasing aztreonam–avibactam MICs in clinical trials; however, in the clinical dataset, there were few Enterobacterales isolates with aztreonam–avibactam MICs of > 4 mg/l. Conclusions MIC distributions and JPTA simulations supported a susceptible MIC breakpoint for aztreonam–avibactam against Enterobacterales of ≤ 8 mg/l. However, limited clinical outcomes data for Enterobacterales with aztreonam–avibactam MIC ≥ 4 mg/l justified the more conservative breakpoints established by EUCAST. Clinical Trial Registration ClinicalTrials.gov, NCT03329092 and NCT03580044. Studies/analyses sponsored by Pfizer.
- 21 November 2025
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (1) , 183-195
Open AccessMicrobiological, Clinical, and Pharmacokinetic/Pharmacodynamic Data to Support EUCAST Aztreonam–Avibactam Minimum Inhibitory Concentration Susceptibility Breakpoints Against Enterobacterales
Introduction Aztreonam–avibactam was approved for adults with limited treatment options for multiple infections due to aerobic Gram-negative organisms in the European Union and for complicated intra-abdominal infection in the US, following the phase 3 REVISIT and ASSEMBLE trials. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) assigned minimum inhibitory concentration (MIC) breakpoints for aztreonam–avibactam against Enterobacterales of susceptible ≤ 4 mg/l and resistant > 4 mg/l. Methods A comprehensive synthesis of data supporting MIC breakpoint determination is summarized, including: joint probability of pharmacokinetic/pharmacodynamic target attainment (JPTA) analyses (based on population pharmacokinetic modeling) for aztreonam–avibactam dose selection; MIC distributions of target pathogens; clinical and microbiological efficacy outcomes; and exposure–response analyses. Results Among 100,228 Enterobacterales isolates, including 2449 metallo-β-lactamase-positive isolates from global surveillance studies (2017–2021), 99% had aztreonam–avibactam MICs of ≤ 8 mg/l. At MIC = 8 mg/l, the predicted JPTA at steady state was 89% to > 99% across subgroups of varying renal function, based on approved doses for aztreonam–avibactam. Clinical trial isolates fell within the same MIC distribution as surveillance studies. There was no evidence of decreased favorable microbiological responses with increasing aztreonam–avibactam MICs in clinical trials; however, in the clinical dataset, there were few Enterobacterales isolates with aztreonam–avibactam MICs of > 4 mg/l. Conclusions MIC distributions and JPTA simulations supported a susceptible MIC breakpoint for aztreonam–avibactam against Enterobacterales of ≤ 8 mg/l. However, limited clinical outcomes data for Enterobacterales with aztreonam–avibactam MIC ≥ 4 mg/l justified the more conservative breakpoints established by EUCAST. Clinical Trial Registration ClinicalTrials.gov, NCT03329092 and NCT03580044. Studies/analyses sponsored by Pfizer.
- Open Access
- 6 August 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (8) , e0195024
Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients
Aztreonam-avibactam, a fixed-ratio (3:1) β-lactam/β-lactamase inhibitor combination, was approved in Europe in 2024 for adults with complicated intra-abdominal infection (cIAI), complicated urinary tract infection, hospital-acquired/ventilator-associated pneumonia, and other infections due to aerobic gram-negative organisms with limited treatment options. Pharmacokinetic data from two phase 3 trials were added to previous data to develop a simultaneous aztreonam and avibactam population pharmacokinetic model. The final model was used to simulate exposures by infection type and renal function and estimate the joint probability of pharmacodynamic target attainment (PTA) for phase 3 patients (aztreonam 60% f T >MIC ATM-AVI of 8 mg/L and avibactam 50% f T >C T of 2.5 mg/L). Additional simulations evaluated simplified loading doses, regimens for end-stage renal disease, and ceftazidime-avibactam + aztreonam regimens. The final model included 4,914 aztreonam plasma samples (431 subjects) and 18,222 avibactam plasma samples (2,635 subjects). A two-compartment model with zero-order infusion and first-order elimination best fit the data. Time-varying creatinine clearance was a key covariate on clearance for both drugs, whereas infection type was a key covariate on clearance and volume, with the lowest exposures observed in patients with cIAI. Final aztreonam-avibactam dose regimens achieved joint PTA 89% to >99% at steady state across renal function groups. Ceftazidime-avibactam + aztreonam dose regimens proposed by the Infectious Diseases Society of America (IDSA) achieved joint PTA <85% due to insufficient avibactam exposures. Approved aztreonam-avibactam dose regimens (single loading dose and regular maintenance doses, all 3 h intravenous infusions) are optimized for joint PTA across renal function groups and infection types. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT03329092 and NCT03580044 .
- 6 August 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (8) , e0195024
Open AccessPopulation pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients
Aztreonam-avibactam, a fixed-ratio (3:1) β-lactam/β-lactamase inhibitor combination, was approved in Europe in 2024 for adults with complicated intra-abdominal infection (cIAI), complicated urinary tract infection, hospital-acquired/ventilator-associated pneumonia, and other infections due to aerobic gram-negative organisms with limited treatment options. Pharmacokinetic data from two phase 3 trials were added to previous data to develop a simultaneous aztreonam and avibactam population pharmacokinetic model. The final model was used to simulate exposures by infection type and renal function and estimate the joint probability of pharmacodynamic target attainment (PTA) for phase 3 patients (aztreonam 60% f T >MIC ATM-AVI of 8 mg/L and avibactam 50% f T >C T of 2.5 mg/L). Additional simulations evaluated simplified loading doses, regimens for end-stage renal disease, and ceftazidime-avibactam + aztreonam regimens. The final model included 4,914 aztreonam plasma samples (431 subjects) and 18,222 avibactam plasma samples (2,635 subjects). A two-compartment model with zero-order infusion and first-order elimination best fit the data. Time-varying creatinine clearance was a key covariate on clearance for both drugs, whereas infection type was a key covariate on clearance and volume, with the lowest exposures observed in patients with cIAI. Final aztreonam-avibactam dose regimens achieved joint PTA 89% to >99% at steady state across renal function groups. Ceftazidime-avibactam + aztreonam dose regimens proposed by the Infectious Diseases Society of America (IDSA) achieved joint PTA <85% due to insufficient avibactam exposures. Approved aztreonam-avibactam dose regimens (single loading dose and regular maintenance doses, all 3 h intravenous infusions) are optimized for joint PTA across renal function groups and infection types. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT03329092 and NCT03580044 .
- Open Access
- 29 June 2020
- Published by Springer Nature in Drug Safety
- Vol. 43 (8) , 751-766
Safety Profile of Ceftazidime–Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme
Introduction Ceftazidime–avibactam combines the established anti-pseudomonal cephalosporin, ceftazidime, with the novel non-β-lactam β-lactamase inhibitor, avibactam. Objectives The aim of this study was to evaluate the safety of ceftazidime–avibactam in adults using pooled data from two phase II (NCT00690378, NCT00752219) and five phase III (NCT01499290, NCT01726023, NCT01644643, NCT01808093 and NCT01595438/NCT01599806) clinical studies. Methods Safety data from seven multicentre, randomised, active-comparator studies were pooled by study group at the patient level for descriptive analyses, comprising patients with complicated urinary tract infection (cUTI), including pyelonephritis, complicated intra-abdominal infection (cIAI), or nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP), treated with ceftazidime–avibactam ± metronidazole or comparator. Results In total, 4050 patients (ceftazidime–avibactam ± metronidazole, n = 2024; comparator, n = 2026) were included in the pooled analysis. Adverse events (AEs) up to the last study visit occurred in 996 (49.2%) and 965 (47.6%) patients treated with ceftazidime–avibactam ± metronidazole and comparator, respectively. The most common AEs across treatment groups were diarrhoea, nausea, headache, vomiting and pyrexia. There were few discontinuations due to AEs (2.5% and 1.7% for ceftazidime–avibactam ± metronidazole and comparators, respectively). Overall rates of serious AEs were 8.7% for ceftazidime–avibactam ± metronidazole and 7.2% for comparators; respective rates of AEs with an outcome of death were 2.0% and 1.8%. AEs considered causally related to the study drug or procedures occurred in 10.7% and 9.6% of patients treated with ceftazidime–avibactam ± metronidazole and comparators; the most common drug-related AEs in both groups were diarrhoea, headache, nausea and increased alanine aminotransferase. No impact to the safety profile of ceftazidime–avibactam ± metronidazole was found with regard to intrinsic factors, such as age or renal function at baseline, or extrinsic factors, such as geographical origin. Potentially clinically significant changes in laboratory parameters were infrequent with no trends or safety concerns identified. Conclusion The observed safety profile of ceftazidime–avibactam across infection types is consistent with the established safety profile of ceftazidime monotherapy and no new safety findings were identified. This analysis supports the use of ceftazidime–avibactam as a treatment option in adults with cUTI, cIAI and NP, including VAP.
- 29 June 2020
- Published by Springer Nature in Drug Safety
- Vol. 43 (8) , 751-766
Open AccessSafety Profile of Ceftazidime–Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme
Introduction Ceftazidime–avibactam combines the established anti-pseudomonal cephalosporin, ceftazidime, with the novel non-β-lactam β-lactamase inhibitor, avibactam. Objectives The aim of this study was to evaluate the safety of ceftazidime–avibactam in adults using pooled data from two phase II (NCT00690378, NCT00752219) and five phase III (NCT01499290, NCT01726023, NCT01644643, NCT01808093 and NCT01595438/NCT01599806) clinical studies. Methods Safety data from seven multicentre, randomised, active-comparator studies were pooled by study group at the patient level for descriptive analyses, comprising patients with complicated urinary tract infection (cUTI), including pyelonephritis, complicated intra-abdominal infection (cIAI), or nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP), treated with ceftazidime–avibactam ± metronidazole or comparator. Results In total, 4050 patients (ceftazidime–avibactam ± metronidazole, n = 2024; comparator, n = 2026) were included in the pooled analysis. Adverse events (AEs) up to the last study visit occurred in 996 (49.2%) and 965 (47.6%) patients treated with ceftazidime–avibactam ± metronidazole and comparator, respectively. The most common AEs across treatment groups were diarrhoea, nausea, headache, vomiting and pyrexia. There were few discontinuations due to AEs (2.5% and 1.7% for ceftazidime–avibactam ± metronidazole and comparators, respectively). Overall rates of serious AEs were 8.7% for ceftazidime–avibactam ± metronidazole and 7.2% for comparators; respective rates of AEs with an outcome of death were 2.0% and 1.8%. AEs considered causally related to the study drug or procedures occurred in 10.7% and 9.6% of patients treated with ceftazidime–avibactam ± metronidazole and comparators; the most common drug-related AEs in both groups were diarrhoea, headache, nausea and increased alanine aminotransferase. No impact to the safety profile of ceftazidime–avibactam ± metronidazole was found with regard to intrinsic factors, such as age or renal function at baseline, or extrinsic factors, such as geographical origin. Potentially clinically significant changes in laboratory parameters were infrequent with no trends or safety concerns identified. Conclusion The observed safety profile of ceftazidime–avibactam across infection types is consistent with the established safety profile of ceftazidime monotherapy and no new safety findings were identified. This analysis supports the use of ceftazidime–avibactam as a treatment option in adults with cUTI, cIAI and NP, including VAP.
- 21 April 2020
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (5)
In Vitro Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial
Nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP), is increasingly associated with multidrug-resistant Gram-negative pathogens. This study describes the in vitro activity of ceftazidime-avibactam, ceftazidime, and relevant comparator agents against bacterial pathogens isolated from patients with NP, including VAP, enrolled in a ceftazidime-avibactam phase 3 trial. Gram-positive pathogens were included if coisolated with a Gram-negative pathogen. In vitro susceptibility was determined at a central laboratory using Clinical and Laboratory Standards Institute broth microdilution methods.
- 21 April 2020
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (5)
In Vitro Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial
Nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP), is increasingly associated with multidrug-resistant Gram-negative pathogens. This study describes the in vitro activity of ceftazidime-avibactam, ceftazidime, and relevant comparator agents against bacterial pathogens isolated from patients with NP, including VAP, enrolled in a ceftazidime-avibactam phase 3 trial. Gram-positive pathogens were included if coisolated with a Gram-negative pathogen. In vitro susceptibility was determined at a central laboratory using Clinical and Laboratory Standards Institute broth microdilution methods.
- 14 June 2018
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 73 (9) , 2519-2523
Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme
This analysis evaluated the clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa isolates pooled from the adult Phase III clinical trials in patients with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) or nosocomial pneumonia (NP) including ventilator-associated pneumonia (VAP). Baseline isolates from five Phase III randomized controlled trials of ceftazidime/avibactam versus predominantly carbapenem comparators in patients with cIAI (RECLAIM 1 and 2; NCT01499290 and RECLAIM 3; NCT01726023), cUTI (RECAPTURE 1 and 2; NCT01595438 and NCT01599806), NP including VAP (REPROVE; NCT01808092) and cIAI or cUTI caused by ceftazidime-non-susceptible Gram-negative pathogens (REPRISE; NCT01644643) were tested for MDR status and susceptibility to ceftazidime/avibactam and carbapenem-based comparators using CLSI broth microdilution methodology. Microbiological and clinical responses for patients with ≥1 MDR Enterobacteriaceae or P. aeruginosa isolate were assessed at the test-of-cure (TOC) visit. In the pooled microbiologically modified ITT population, 1051 patients with MDR Enterobacteriaceae and 95 patients with MDR P. aeruginosa isolates were identified. Favourable microbiological response rates at TOC for all MDR Enterobacteriaceae and MDR P. aeruginosa were 78.4% and 57.1%, respectively, for ceftazidime/avibactam and 71.6% and 53.8%, respectively, for comparators. The proportions of patients with ≥1 MDR isolate who were clinically cured at TOC were similar in the ceftazidime/avibactam (85.4%) and comparator (87.9%) arms. Ceftazidime/avibactam demonstrated similar clinical efficacy to predominantly carbapenem comparators against MDR Enterobacteriaceae and P. aeruginosa, and may be a suitable alternative to carbapenem-based therapies for cIAI, cUTI and NP/VAP caused by MDR Gram-negative pathogens.
- 14 June 2018
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 73 (9) , 2519-2523
Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme
This analysis evaluated the clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa isolates pooled from the adult Phase III clinical trials in patients with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) or nosocomial pneumonia (NP) including ventilator-associated pneumonia (VAP). Baseline isolates from five Phase III randomized controlled trials of ceftazidime/avibactam versus predominantly carbapenem comparators in patients with cIAI (RECLAIM 1 and 2; NCT01499290 and RECLAIM 3; NCT01726023), cUTI (RECAPTURE 1 and 2; NCT01595438 and NCT01599806), NP including VAP (REPROVE; NCT01808092) and cIAI or cUTI caused by ceftazidime-non-susceptible Gram-negative pathogens (REPRISE; NCT01644643) were tested for MDR status and susceptibility to ceftazidime/avibactam and carbapenem-based comparators using CLSI broth microdilution methodology. Microbiological and clinical responses for patients with ≥1 MDR Enterobacteriaceae or P. aeruginosa isolate were assessed at the test-of-cure (TOC) visit. In the pooled microbiologically modified ITT population, 1051 patients with MDR Enterobacteriaceae and 95 patients with MDR P. aeruginosa isolates were identified. Favourable microbiological response rates at TOC for all MDR Enterobacteriaceae and MDR P. aeruginosa were 78.4% and 57.1%, respectively, for ceftazidime/avibactam and 71.6% and 53.8%, respectively, for comparators. The proportions of patients with ≥1 MDR isolate who were clinically cured at TOC were similar in the ceftazidime/avibactam (85.4%) and comparator (87.9%) arms. Ceftazidime/avibactam demonstrated similar clinical efficacy to predominantly carbapenem comparators against MDR Enterobacteriaceae and P. aeruginosa, and may be a suitable alternative to carbapenem-based therapies for cIAI, cUTI and NP/VAP caused by MDR Gram-negative pathogens.
- Top Cited Papers
- 1 March 2018
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 18 (3) , 285-295
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
- 1 March 2018
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 18 (3) , 285-295
Top Cited PapersCeftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
- Open Access
- 1 May 2017
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 49 (5) , 579-588
A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia
- 1 May 2017
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 49 (5) , 579-588
Open AccessA randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia
- 5 July 2013
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 3 (1) , 43-50
Caspofungin exposure-response relationships in adult patients with mucosal or invasive candidiasis
- 5 July 2013
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 3 (1) , 43-50
Caspofungin exposure-response relationships in adult patients with mucosal or invasive candidiasis
- 1 April 2010
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (4) , 1590-1595
Mutant APH(2″)-IIa Enzymes with Increased Activity against Amikacin and Isepamicin
Directed evolution by random PCR mutagenesis of the gene for the aminoglycoside 2″-IIa phosphotransferase generated R92H/D268N and N196D/D268N mutant enzymes, resulting in elevated levels of resistance to amikacin and isepamicin but not to other aminoglycoside antibiotics. Increases in the activities of the mutant phosphotransferases for isepamicin are the result of decreases in K m values, while improved catalytic efficiency for amikacin is the result of both a decrease in K m values and an increase in turnover of the antibiotic. Enzymes with R92H, D268N, and D268N single amino acid substitutions did not result in elevated MICs for aminoglycosides.
- 1 April 2010
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (4) , 1590-1595
Mutant APH(2″)-IIa Enzymes with Increased Activity against Amikacin and Isepamicin
Directed evolution by random PCR mutagenesis of the gene for the aminoglycoside 2″-IIa phosphotransferase generated R92H/D268N and N196D/D268N mutant enzymes, resulting in elevated levels of resistance to amikacin and isepamicin but not to other aminoglycoside antibiotics. Increases in the activities of the mutant phosphotransferases for isepamicin are the result of decreases in K m values, while improved catalytic efficiency for amikacin is the result of both a decrease in K m values and an increase in turnover of the antibiotic. Enzymes with R92H, D268N, and D268N single amino acid substitutions did not result in elevated MICs for aminoglycosides.
- 31 March 2009
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 33 (3) , 295
Corrigendum to “In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia–Pacific region: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)” [Int. J. Antimicrob. Agents 28 (2006) 238–243]
- 31 March 2009
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 33 (3) , 295
Corrigendum to “In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia–Pacific region: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)” [Int. J. Antimicrob. Agents 28 (2006) 238–243]